NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

Rhea-AI Summary

NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its financial results for the fourth quarter and full year of 2022 on March 2, 2023, after market close. The webcast of the conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET, accessible on their website for live and archived listening.

The company focuses on innovative epilepsy treatment solutions, particularly with its RNS System, designed to provide personalized, brain-responsive therapy to patients experiencing drug-resistant epilepsy. NeuroPace aims to enhance care standards and patient outcomes in managing seizures.

Positive

• The RNS System is the only commercially available brain-responsive platform for epilepsy treatment.
• Potential to improve outcomes for a significant number of patients with drug-resistant epilepsy.

Negative

• None.

MOUNTAIN VIEW, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 2, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.neuropace.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.

About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:
Gilmartin Group
Philip Trip Taylor
investors@neuropace.com

FAQ

What are NeuroPace's upcoming financial results announcement dates?

NeuroPace will announce its financial results for Q4 and full year 2022 on March 2, 2023.

What time is the NeuroPace earnings call scheduled?

The earnings call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on March 2, 2023.

How can investors access the NeuroPace conference call?

Investors can access the conference call via a live and archived webcast on NeuroPace's website.

What innovation does the RNS System offer for epilepsy treatment?

The RNS System offers a personalized, brain-responsive treatment for patients with drug-resistant epilepsy.